Streetbeat News

Analyst Ratings

EQ

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Equillium (NASDAQ:EQ) and maintained a price target of $5.5.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:24 am

URGN

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on UroGen Pharma (NASDAQ:URGN) and maintained a price target of $54.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:23 am

GANX

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:22 am

SPRO

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Spero Therapeutics (NASDAQ:SPRO) and raises the price target from $6 to $7.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:22 am

IVVD

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Invivyd (NASDAQ:IVVD) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:21 am

MNKD

HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on MannKind (NASDAQ:MNKD) and raises the price target from $7 to $7.5.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:19 am

ATAI

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on ATAI Life Sciences (NASDAQ:ATAI) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:18 am

SGMO

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Sangamo Therapeutics (NASDAQ:SGMO) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:17 am

TCRX

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on TScan Therapeutics (NASDAQ:TCRX) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:16 am

SVRA

HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Savara (NASDAQ:SVRA) and has raised the price target from $3 to $6.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:16 am